A Novel Biomarker for Post-Transplant Recurrent IgA Nephropathy.

Area of Science:

• Nephrology
• Immunology
• Biomarker Discovery

Background:

• Serum galactose-deficient immunoglobulin A1 (Gd-IgA1) is a key candidate biomarker for IgA nephropathy (IgAN).
• Evaluating Gd-IgA1 as a noninvasive biomarker for post-transplant IgAN recurrence is crucial.

Purpose of the Study:

• To assess serum Gd-IgA1 levels as a biomarker for IgAN recurrence after kidney transplantation.
• To correlate Gd-IgA1 levels with post-transplant outcomes and graft survival.

Main Methods:

• Serum Gd-IgA1 levels were measured using a KM55 enzyme-linked immunosorbent assay (ELISA).
• Levels were compared between patients with recurrent IgAN, non-recurrent IgAN, non-transplant IgAN, and healthy controls.
• The association of Gd-IgA1 with recurrence, post-transplant events, and graft survival was analyzed.

Main Results:

• Recurrent IgAN patients exhibited significantly higher serum Gd-IgA1 levels than non-recurrent IgAN patients (P = .027).
• Non-transplant IgAN patients also showed significantly higher Gd-IgA1 levels compared to non-recurrent IgAN patients and healthy relatives (P < .001 and P = .021).
• Receiver-operating characteristic analysis indicated serum Gd-IgA1 has diagnostic potential for IgAN recurrence (AUC = 0.69, P = .038).
• Allograft rejection and graft failure rates did not significantly differ between recurrent and non-recurrent IgAN groups.

Conclusions:

• A novel lectin-independent Gd-IgA1 ELISA can detect elevated levels in patients with recurrent IgAN.
• Serum Gd-IgA1 serves as a valuable biomarker for diagnosing and assessing the activity of post-transplant recurrent IgAN.